Abstract:A better mechanistic understanding of virus-host dependencies can help reveal vulnerabilities and identify opportunities for therapeutic intervention. Of particular interest are essential interactions that enable production of viral proteins, as those could target an early step in the virus lifecycle. Here, we use subcellular proteomics, ribosome profiling analyses and reporter assays to detect changes in protein synthesis dynamics during SARS-CoV-2 (CoV2) infection. We identify specific translation factors and molecular chaperones that are used by CoV2 to promote the synthesis and maturation of its own proteins. These can be targeted to inhibit infection, without major toxicity to the host. We also find that CoV2 non-structural protein 1 (Nsp1) cooperates with initiation factors EIF1 and 1A to selectively enhance translation of viral RNA. When EIF1/1A are depleted, more ribosomes initiate translation from a conserved upstream CUG start codon found in all genomic and subgenomic viral RNAs. This results in higher translation of an upstream open reading frame (uORF1) and lower translation of the main ORF, altering the stoichiometry of viral proteins and attenuating infection. Replacing the upstream CUG with AUG strongly inhibits translation of the main ORF independently of Nsp1, EIF1, or EIF1A. Taken together, our work describes multiple dependencies of CoV2 on host biosynthetic networks and proposes a model for dosage control of viral proteins through Nsp1-mediated control of translation start site selection. Host-directed antivirals offer a promising therapeutic approach for many viruses, including SARS-CoV-2 (CoV2), but their development requires a deeper understanding of virus-host interactions. Of particular interest are interactions that selectively promote the synthesis of viral proteins, including RNA-binding proteins, translation factors and molecular chaperones. Drugs that inhibit such biosynthetic factors have already entered clinical trials for multiple indications. To identify new cellular targets for intervention, we isolated translating ribosomes from CoV2-infected and control cells and analyzed their interacting partners by mass-spectrometry. We found multiple biosynthetic factors that were specifically enriched on polysomes translating CoV2, including translation initiation factors EIF1 and 1A. These factors control translation start site selection, cooperate with the viral non-structural protein 1 (Nsp1) to selectively enhance translation of viral genomic RNA, and are exploited by CoV2 to regulate the timing and stoichiometry of viral protein synthesis. Targeting EIF1A by siRNA reduces infection with minimal toxicity to the host. Although the nature of interactions between EIF1/1A and Nsp1 remains unclear, this interdependency may provide a new strategy for antiviral therapy.

Translation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised group

Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study

Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study

Humoral and T-cell responses to SARS-CoV-2 vaccination in patients receiving immunosuppression

Effect of Immunosuppression on the Immune Response to SARS-CoV-2 Infection and Vaccination

Role of mTOR inhibitor in the cellular and humoral immune response to a booster dose of SARS-CoV-2 mRNA-1273 vaccine in kidney transplant recipients

The Immunologic Downsides Associated with the Powerful Translation of Current COVID-19 Vaccine mRNA Can Be Overcome by Mucosal Vaccines

Lack of Specific Immune Response after Five Doses of mRNA SARS-CoV-2 Vaccine in a Patient with CD4+ T-Cell Lymphopenia but Preserved Responses to CMV

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID

Differential cellular and humoral immune responses in immunocompromised individuals following multiple SARS-CoV-2 vaccinations

Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort

SARS-CoV-2 Nsp1 cooperates with initiation factors EIF1 and 1A to selectively enhance translation of viral RNA

Clinical and virological features of SARS-CoV-2 Omicron variant-infected immunocompromised patients receiving immunosuppressive medications

In Vitro Profiling of Commonly Used Post-transplant Immunosuppressants Reveals Distinct Impact on Antiviral T-cell Immunity Towards CMV

Comparative effectiveness of mRNA-1273 and BNT162b2 COVID-19 vaccines in immunocompromised individuals: a systematic review and meta-analysis using the GRADE framework

Additive effects of booster mRNA vaccination and SARS-CoV-2 Omicron infection on T cell immunity across immunocompromised states

Effect of antimetabolite regimen on cellular and humoral immune response to SARS-COV-2 vaccination in solid organ transplant recipients.

Perturbations of the T-cell receptor repertoire in response to SARS-CoV-2 in immunocompetent and immunocompromised individuals

The differential effect of SARS-COV-2 NSP1 on mRNA translation and stability reveals new insights linking ribosome recruitment, codon usage and virus evolution

Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: An observational study of real-world data across 10 US states from August-December 2021

Reduced immune response to inactivated SARS-CoV-2 vaccine in a cohort of immunocompromised patients in Chile